Check out our most popular compounded medications! Get Started
Cevimeline Hydrochloride is a muscarinic agonist primarily used to treat symptoms of dry mouth in patients with Sjögren's syndrome.
Cevimeline Hydrochloride is a muscarinic agonist that primarily targets the M3 muscarinic receptors, which are predominantly found in exocrine glands such as salivary and sweat glands. This API is particularly effective in stimulating salivary secretion, making it a valuable treatment option for patients suffering from xerostomia, commonly associated with Sjögren's syndrome. By enhancing the secretion of saliva, Cevimeline Hydrochloride helps alleviate the discomfort of dry mouth, improving oral health and overall quality of life for affected individuals.
In addition to its primary use in managing dry mouth, Cevimeline Hydrochloride may also have potential benefits in treating other conditions characterized by reduced glandular secretion. Its mechanism of action involves binding to muscarinic receptors, which leads to increased intracellular calcium levels and subsequent stimulation of glandular cells. This targeted action ensures that Cevimeline Hydrochloride effectively enhances glandular function without significantly affecting other bodily systems, thereby minimizing potential side effects.
Prescribers should consider the pharmacokinetic profile of Cevimeline Hydrochloride when determining the appropriate dosage for patients. The API is well-absorbed orally, with peak plasma concentrations typically reached within 1.5 to 2 hours post-administration. It is metabolized primarily in the liver, and its elimination half-life is approximately 5 hours, allowing for convenient dosing schedules. Understanding these pharmacokinetic properties can aid healthcare providers in optimizing treatment regimens to achieve the desired therapeutic outcomes.
While Cevimeline Hydrochloride is generally well-tolerated, prescribers should be aware of potential side effects, which may include sweating, nausea, and rhinitis. These effects are generally mild and transient, but monitoring is advised, especially in patients with pre-existing conditions that may be exacerbated by increased cholinergic activity. By carefully considering the individual needs and medical history of each patient, healthcare providers can effectively incorporate Cevimeline Hydrochloride into their therapeutic arsenal to manage conditions associated with reduced glandular secretion.
Each of these is compounded to order at our Warwick, Rhode Island pharmacy and requires a prescription.
We do not have a patient page for this ingredient yet. That does not mean we cannot make it. Bayview compounds this ingredient to a prescriber's order, and our full compounding formulary lists every preparation we make. Viewing the formulary requires a prescriber account.
Prescriber sign inA sample of preparations from our formulary. Strengths and dose forms are customised to the prescription.
Other salt forms of this molecule, and ingredients commonly compounded alongside it.
This page describes an active pharmaceutical ingredient, not a finished drug product. Bayview Pharmacy compounds preparations containing it only on a prescriber's order for an individual patient.
Compounded preparations are not FDA-approved, and the FDA has not evaluated them for safety, effectiveness, or manufacturing quality. Nothing on this page is a claim that any preparation is effective for any condition.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice — discuss your situation with a licensed healthcare provider.
Our pharmacists work with prescribers to build preparations around a patient's dose, form and tolerances. Ask us what is possible with this ingredient.
